Imagine trying to fight a stubborn fire that keeps coming back; sometimes water alone isn't enough, and you need to add heat-blocking foam. This study checks if adding radiation to a specific chemotherapy drug works better than the drug alone for brain tumors. It's like testing a recipe in a real kitchen rather than a lab to see what actually works for most people.
Recurrent glioblastoma has a dismal prognosis and high symptom burden, with no clear, evidence-based standard for whether adding radiation to chemotherapy is more effective or cost-efficient.
A phase III randomized pragmatic clinical trial and a cost-effectiveness model to evaluate combined radiation and lomustine chemotherapy.
If you are a generic drug manufacturer dealing with stagnant sales of lomustine — this project developed a new evidence-based standard of care that could increase the clinical demand for this chemotherapy. By proving the efficacy of combined therapy, the drug's role in the treatment protocol is strengthened.
If you are a radiation equipment provider dealing with fluctuating demand for reirradiation services — this project developed clinical evidence on whether adding radiation to chemotherapy is superior. This could lead to more hospitals adopting reirradiation as a standard practice for recurrent glioblastoma.
If you are a health economics consultancy dealing with inefficient cancer care spending — this project developed a cost-effectiveness analysis to investigate the economic value of combined treatment. This data helps in creating evidence-informed policy decisions for health system sustainability.
Based on available project data, specific pricing is not provided, but the project is performing a cost-effectiveness analysis to determine the economic value of adding radiation to chemotherapy.
The project is currently in a phase III clinical trial with 42 clinical sites across 11 countries, indicating it is testing the treatment in a real-world clinical setting.
Based on available project data, there is no mention of patents or licensing; it is an investigator-initiated study aimed at defining a new standard of care.
Patient recruitment is expected to be completed by June 2027, with the overall project period ending on 2028-05-31.
The study uses minimal patient eligibility criteria to ensure the results are as close as possible to routine clinical settings, facilitating easier integration into standard care.
The consortium is composed of 6 partners from 6 countries, showing a strong European reach. It has a balanced mix of 2 universities, 2 research organizations, 1 industry partner, and 1 other entity. With an industry ratio of 17% and 2 SMEs involved, the group is heavily weighted toward clinical and academic research, coordinated by the European Organisation for Research and Treatment of Cancer.
Contact the European Organisation for Research and Treatment of Cancer AISBL in Belgium
Contact us to track the phase III results for glioblastoma treatment standards.
